Last Updated: November 16, 2026

Details for Patent: 9,987,262

« Back to Dashboard


Which drugs does patent 9,987,262 protect, and when does it expire?

Patent 9,987,262 protects VAFSEO and is included in one NDA.

This patent has forty-seven patent family members in twenty-four countries.

Summary for Patent: 9,987,262
Title:Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
Abstract:Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
Inventor(s):James Densmore Copp, Ann W. Newman, Anne Luong
Assignee: Akebia Therapeutics Inc
Application Number:US15/608,186
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,987,262
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

US Patent 9,987,262: Scope, Claim Construction, Expiration and Vadadustat Patent Landscape

US Patent 9,987,262 protects a specific crystalline form of Compound (I), identified in the patent family as vadadustat, when used to treat anemia. Its principal limitation is physical form: the active ingredient must exhibit a defined X-ray powder diffraction pattern. The claims also cover compositions containing that form, chronic-kidney-disease anemia, high chemical purity, low levels of other polymorphs or amorphous material, and control of a specified manufacturing impurity.

The patent was issued June 5, 2018. Based on its earliest nonprovisional/PCT filing chronology, the ordinary statutory expiration is in July 2035, subject to any patent-term adjustment. The patent is a small-molecule product-form and method-of-use patent, not a biologic patent.

What does US Patent 9,987,262 protect?

The patent protects methods of administering a defined crystalline form of Compound (I) to an anemia patient. It does not broadly claim every form of vadadustat, every anemia treatment, or every formulation containing vadadustat.

The operative limitations are:

Limitation Claim requirement
Active ingredient Crystalline Compound (I)
Solid form XRPD peaks at approximately 18.1, 20.3, 22.9, 24.0 and 26.3° 2θ, each within ±0.2°
Therapeutic use Treatment of anemia
Administration A therapeutically effective amount administered to a patient
Composition route Claims 2, 4, 6, 8, 12, 13 and 14 require administration of a pharmaceutical composition
Disease subgroup Claims 3, 4, 7 and 8 cover anemia secondary to or associated with chronic kidney disease
Polymorphic purity Less than 5% by weight of any other crystalline form
Chemical purity At least 99.5% purity by HPLC
Impurity control Less than 100 ppm of Formula (II) by GC/MS
Amorphous content Less than 5% by weight of amorphous Compound (I)
XRPD alternative Claim 15 uses the pattern shown in Figure 1 rather than listing only the five numerical peaks

Claims 1 and 2 are the two principal independent claims. Claim 15 is a separate independent method claim. Claims 3 through 14 narrow those methods with disease, purity, polymorph, amorphous-content or impurity limitations.

What is the identity of Compound (I) in US 9,987,262?

Compound (I) is vadadustat, an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI. Vadadustat is marketed in the United States as Vafseo for anemia due to chronic kidney disease in adults on dialysis.

The patent's claim strategy does not rely only on the chemical identity of vadadustat. It relies on the solid-state form administered to the patient. That distinction matters because a generic applicant could attempt to use a different polymorph, amorphous material, hydrate, solvate or other solid form while still using the same active moiety.

How do claims 1 through 15 differ?

Claims 1 and 2: broadest asserted method claims

Claim 1 covers administration of the crystalline form itself. Claim 2 covers administration of a pharmaceutical composition containing the crystalline form.

The word "comprising" generally permits additional ingredients, excipients and processing components. Claim 2 therefore does not require the composition to consist only of vadadustat and the claimed crystalline form.

The claims still require proof that the administered material satisfies the specified XRPD requirement. A formulation containing chemically identical vadadustat but a different solid form would not automatically fall within the claims.

Claims 3, 4, 7 and 8: chronic kidney disease anemia

These claims narrow the indication to anemia secondary to or associated with chronic kidney disease. They are commercially important because Vafseo's approved U.S. indication is CKD-associated anemia.

The claims do not expressly limit the patient to dialysis or non-dialysis status. A method directed to a CKD-anemia patient could potentially fall within the claim even if the patient subgroup differs from the approved Vafseo label, provided all other limitations are met.

Claims 5, 6, 11 and 14: solid-state purity

These claims require low quantities of competing solid forms:

  • Less than 5% of any other crystalline form.
  • Less than 5% of amorphous Compound (I).

These limitations are directed to polymorphic control. They may be relevant to commercial drug substance and finished tablets because manufacturing specifications commonly define polymorphic composition, crystallinity and batch consistency.

A product with more than 5% of another crystalline form or amorphous material would have an argument against literal infringement of the relevant dependent claim. That does not necessarily avoid claims 1, 2 or 15 if the XRPD pattern still falls within those claims.

Claims 9 and 12: HPLC chemical purity

Claims 9 and 12 require at least 99.5% purity by HPLC. This is a chemical assay limitation, not a solid-state limitation. A product may satisfy the XRPD requirement while failing the HPLC threshold, or satisfy the HPLC threshold while using the wrong polymorph.

Claims 10 and 13: Formula (II) impurity

Claims 10 and 13 limit the specified impurity to less than 100 ppm by GC/MS. The claim uses a particular analytical method, making the test methodology material to infringement analysis.

The impurity limitation may be especially relevant to process development. A competing manufacturer could use an alternative process that produces the same crystalline form but different impurity levels. If the impurity remains below 100 ppm, the dependent claim may still be implicated.

Claim 15: Figure-based XRPD limitation

Claim 15 requires the crystalline form to have an XRPD pattern "as shown in FIG. 1." This claim may be broader or narrower than the five-peak formulation in claims 1 and 2, depending on how the figure is construed and how much of the pattern is treated as limiting.

For enforcement, the patent owner would likely compare the accused material's complete XRPD pattern, peak positions, relative intensities and analytical conditions with Figure 1 and the specification.

What is the patent's technical scope?

The patent covers the following technical subject matter:

  1. A particular crystalline form of vadadustat.
  2. Use of that form to treat anemia.
  3. Use in CKD-associated anemia.
  4. Pharmaceutical compositions containing the form.
  5. Control of other crystalline forms.
  6. Control of amorphous vadadustat.
  7. High HPLC purity.
  8. Low levels of a specified volatile or process-related impurity.
  9. A defined XRPD fingerprint.

The patent does not, on the supplied claims, expressly cover:

  • Every polymorph of vadadustat.
  • Every amorphous form of vadadustat.
  • The chemical compound independent of physical form.
  • A composition that contains only a different vadadustat form.
  • Manufacturing the claimed crystal.
  • A process for crystallizing the claimed form.
  • A particular dose, dosing frequency or route beyond administration.
  • A specific tablet excipient system.
  • Treatment of diseases other than anemia.

When does US Patent 9,987,262 expire?

US Patent 9,987,262 was granted on June 5, 2018. Its priority and filing history place the ordinary patent-term endpoint in July 2035. The operative date should be checked against the USPTO Patent Term Calculator and the patent's recorded term adjustment.

Event Date
Earliest priority period 2014
U.S. or PCT filing period July 2015
Publication January 2016
Patent grant June 5, 2018
Estimated ordinary expiration July 2035
Patent-term adjustment Must be confirmed from USPTO records

The patent term is separate from FDA regulatory exclusivity. A patent may remain enforceable after FDA exclusivity ends, and a patent challenge may be filed before the patent expires.

What is the FDA and Orange Book status of the protected product?

Vafseo, containing vadadustat, was approved by FDA on March 27, 2024, under NDA 215166 for anemia due to CKD in adults on dialysis. FDA approval established the regulatory product associated with the patent estate, but the approval itself does not determine the full scope of patent claims.

Vadadustat is a small-molecule drug. The relevant abbreviated pathway is an ANDA, not a biosimilar application under section 351(k) of the Public Health Service Act.

Orange Book questions are product-specific:

  • The relevant listed drug is Vafseo.
  • The patent may be listed if it claims the drug substance, drug product or approved method of use under FDA's patent-listing rules.
  • A method-of-use listing may have narrower commercial effect than a drug-product or composition listing.
  • The exact Orange Book listing, use code and expiration date should be distinguished from the patent's broader disclosure.

The claims supplied here are method claims focused on administration of a crystalline form. They are not conventional composition claims that claim a tablet as such. That distinction may affect Orange Book listing eligibility and the scope of any use code.

Is there a Paragraph IV challenge risk?

Yes. A generic applicant could submit an ANDA with a Paragraph IV certification alleging that the relevant patent is invalid, unenforceable or not infringed.

The principal challenge routes would include:

Challenge theory Potential target
Non-infringement Use a different polymorph, amorphous form or XRPD profile
Anticipation Identify an earlier reference disclosing the same crystalline form and use
Obviousness Combine prior-art crystallization and anemia-treatment disclosures
Claim construction Contest whether peaks or Figure 1 define the claimed form
Analytical variability Challenge reproducibility of XRPD, HPLC or GC/MS limits
Enablement or written description Contest the breadth of the claimed patient-treatment scope
Patent listing Challenge whether the patent is properly listed for the approved product

A non-infringing ANDA design would likely require careful solid-state characterization. Merely changing tablet excipients would not necessarily avoid infringement if the same claimed crystalline vadadustat is administered.

For an NCE-approved product, FDA generally provides five years of marketing exclusivity, subject to the statutory exceptions for Paragraph IV submissions. With a March 27, 2024 approval, the ordinary NCE exclusivity period would extend to March 27, 2029. Patent rights may extend to approximately July 2035.

Are biosimilar risks relevant to Vafseo?

No. Vadadustat is a chemically synthesized small molecule, not a biologic. Biosimilar substitution and 351(k) litigation do not apply.

The competitive entry risk is generic-drug risk through an ANDA. A generic applicant would need to address the innovator's listed patents and regulatory exclusivity through certifications and, where applicable, patent litigation.

Which competing drugs affect the vadadustat patent landscape?

The principal competitive HIF-PHI products and development programs include:

Drug Company Regulatory position in the United States Relevance
Vadadustat Akebia Therapeutics FDA-approved as Vafseo Direct protected product
Daprodustat GlaxoSmithKline FDA-approved as Jesduvroq Competing HIF-PHI
Roxadustat FibroGen and AstraZeneca Not approved in the United States International competitor
Molidustat Bayer Not approved in the United States Development and international competition
Erythropoiesis-stimulating agents Multiple companies Established treatments Commercial substitutes
Hypoxia-inducible factor pathway agents Multiple developers Product-specific Potential future competition

These products do not automatically infringe US 9,987,262. The patent requires the claimed crystalline Compound (I), not merely any HIF-PHI or any anemia treatment.

How strong is the patent estate?

The patent is strongest against a product that:

  1. Uses vadadustat;
  2. Administers the same claimed crystalline form;
  3. Has the claimed XRPD peaks;
  4. Is used for anemia or CKD-associated anemia; and
  5. Meets the dependent purity specifications.

Its strength is lower against:

  • A different vadadustat polymorph;
  • A material that is predominantly amorphous;
  • A product with a materially different XRPD profile;
  • A non-vadadustat HIF-PHI;
  • A product used outside anemia;
  • A process that generates a different solid form.

The estate's commercial value depends on whether additional patents cover the vadadustat molecule, manufacturing process, formulation, dosing regimen or approved use. US 9,987,262 alone should not be treated as a complete freedom-to-operate analysis for Vafseo.

What patent litigation and settlement issues should be monitored?

The relevant litigation trigger would be an ANDA Paragraph IV notice involving Vafseo's listed patents. A timely infringement action could trigger a 30-month FDA approval stay under the Hatch-Waxman framework, subject to statutory exceptions and court decisions.

The supplied claims do not establish that a Paragraph IV notice, district-court case or settlement has occurred. No settlement terms, authorized-generic arrangement or launch date can be inferred from the patent claims themselves.

Key litigation issues would include:

  • Whether the ANDA product contains the patented crystalline form.
  • Whether the XRPD peaks are inherent in the proposed generic material.
  • Whether the patent claims are invalid for obviousness.
  • Whether the patent is properly listed for Vafseo.
  • Whether the proposed labeling induces infringement of the anemia or CKD method claims.
  • Whether a settlement permits an early generic launch before July 2035.

What geographic coverage does the patent provide?

US 9,987,262 provides rights only in the United States. Corresponding patent-family members may exist in Europe, Japan, Canada, China and other jurisdictions, but foreign rights require separate claim and status analysis.

A U.S. patent does not block:

  • Manufacture and sale solely outside the United States;
  • Foreign use of a different crystalline form;
  • Importation into the United States of material that does not meet the asserted claims;
  • Foreign commercialization where the corresponding national patent has expired or was not granted.

International patent protection for the same crystal form may have different expiration dates, claim scope and validity outcomes.

Key Takeaways

  • US 9,987,262 is a crystalline-form and method-of-use patent for vadadustat.
  • The core requirement is an XRPD pattern with peaks at approximately 18.1, 20.3, 22.9, 24.0 and 26.3° 2θ.
  • Claims cover treatment of anemia, including CKD-associated anemia.
  • Several dependent claims impose less-than-5% polymorph or amorphous limits, at least 99.5% HPLC purity and less than 100 ppm of Formula (II).
  • Claim 15 separately relies on the XRPD pattern shown in Figure 1.
  • The patent was granted June 5, 2018, with ordinary expiration in July 2035, subject to USPTO term adjustment.
  • Vafseo was FDA-approved March 27, 2024, for anemia due to CKD in adults on dialysis.
  • Generic entry would proceed through an ANDA, not a biosimilar application.
  • A generic using a different solid form may have a credible non-infringement strategy, but it would require extensive XRPD and solid-state characterization.
  • The patent does not independently establish coverage of every vadadustat formulation, manufacturing process or dose regimen.

FAQs

Does US 9,987,262 cover all forms of vadadustat?

No. The supplied claims require a defined crystalline form identified by XRPD characteristics. Other polymorphs and amorphous material are not automatically covered.

Can a generic avoid the patent by changing tablet excipients?

Not necessarily. If the generic still administers the claimed crystalline form, changing excipients may not avoid the method claims.

Does the patent cover anemia unrelated to chronic kidney disease?

Claims 1, 2 and 15 are not expressly limited to CKD-associated anemia. Claims 3, 4, 7 and 8 add the CKD-related limitation.

Is vadadustat subject to biosimilar competition?

No. Vadadustat is a small-molecule drug. The relevant pathway is an ANDA for a generic product.

What evidence is most important in a validity or infringement dispute?

The critical evidence would include XRPD data, reference standards, polymorph and amorphous content, HPLC purity, GC/MS impurity results, batch records, drug-substance specifications and the proposed generic product's labeling.

References

  1. Akebia Therapeutics, Inc. (2018). Crystalline forms of a compound useful for treating anemia, U.S. Patent No. 9,987,262. United States Patent and Trademark Office.

  2. U.S. Food and Drug Administration. (2024). Vafseo (vadadustat) prescribing information. FDA.

  3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

  4. U.S. Food and Drug Administration. (2024). Approved drug products: Vafseo, NDA 215166. FDA Drugs@FDA.

  5. United States Code, 35 U.S.C. §§ 154, 156, 271 and 282.

  6. United States Code, 21 U.S.C. § 355.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,987,262

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Akebia VAFSEO vadadustat TABLET;ORAL 215192-001 Mar 27, 2024 RX Yes No ⤷  Start Trial ⤷  Start Trial TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS ⤷  Start Trial
Akebia VAFSEO vadadustat TABLET;ORAL 215192-002 Mar 27, 2024 RX Yes No ⤷  Start Trial ⤷  Start Trial TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS ⤷  Start Trial
Akebia VAFSEO vadadustat TABLET;ORAL 215192-003 Mar 27, 2024 DISCN Yes No ⤷  Start Trial ⤷  Start Trial TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.